Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
SandoSTATIN
(United States) [Available] ,Mycapssa
(United States) [Available] ,SandoSTATIN LAR Depot
(United States) [Available]Synonyms :
octreotide
Class :
Gastrointestinal agents; Antidiarrheal drugs/Somatostatin analogs; Antisecretory agents
Brand Name :
SandoSTATIN
(United States) [Available] ,Mycapssa
(United States) [Available] ,SandoSTATIN LAR Depot
(United States) [Available]Synonyms :
octreotide
Class :
Gastrointestinal agents; Antidiarrheal drugs/Somatostatin analogs; Antisecretory agents
Dosage Forms & Strengths
Capsule, delayed-release
20mg
Injectable solution
0.05mg/mL
0.1mg/mL
0.2mg/mL
0.5mg/mL
1mg/mL
50 - 200
mg
Solution
Subcutaneous (SC)
every 8 hrs
2 - 12
days
Dosage Forms & Strengths
Capsule, delayed-release
20mg
Injectable solution
0.05mg/mL
0.1mg/mL
0.2mg/mL
0.5mg/mL
1mg/mL
Refer adult dosing
octreotide: they may diminish the serum concentration of telotristat ethyl
octreotide: they may diminish the serum concentration of antacids
octreotide: they may diminish the serum concentration of hormonal contraceptives
octreotide: they may diminish the serum concentration of hormonal contraceptives
octreotide: they may diminish the serum concentration of hormonal contraceptives
octreotide: they may diminish the serum concentration of hormonal contraceptives
octreotide: they may diminish the serum concentration of hormonal contraceptives
QT-prolonging Strong may enhance the QTc-prolonging effect of delamanid
may enhance the QTc-prolonging effect of Fluorouracil Products
may have an increased QTc-prolonging effect when combined with domperidone
may have an increased QTc-prolonging effect when combined with astemizole
may have an increased QTc-prolonging effect when combined with bedaquiline
may have an increased QTc-prolonging effect when combined with chloroquine
may have an increased QTc-prolonging effect when combined with chlorpromazine
may have an increased QTc-prolonging effect when combined with cisapride
may have an increased QTc-prolonging effect when combined with clofazimine
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with clozapine
may have an increased QTc-prolonging effect when combined with dasatinib
May enhance the QTc-prolonging effect of each other when combined
escitalopram: they may increase the QTc-prolonging effect of QTc-prolonging Agents
imipramine: they may increase the QTc-prolonging effect of QTc-prolonging agents
inotuzumab: they may enhance the QTc-prolonging effect of QTc-prolonging agents
lofexidine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propafenone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
vemurafenib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ceritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
amiodarone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
flecainide: they may increase the QTc-prolonging effect of QTc-prolonging Agents
pilsicainide HCL: they may increase the QTc-prolonging effect of QTc-prolonging Agents
darunavir: it may increase the risk or severity of QTc prolongation
bradycardia agents increase the arrhythmogenic impact of fexinidazole
somatostatin analogs decrease the diagnostic effect of macimorelin
may enhance the QTc-prolonging effect of Nilotinib
may have an increased QTc-prolonging effect when combined with flupentixol
may have an increased QTc-prolonging effect when combined with levoketoconazole
QT-prolonging Agents (Highest Risk) may increase Citalopram's ability to prolong QTc
QT-prolonging agents (Highest Risk) may increase clarithromycin's ability to prolong QTc
thiazide and it’s like diuretics increase the effect of QTc prolongation
May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
entrectinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
moxifloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
nilotinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
piperaquine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
antacids reduce the concentration of octreotide in the serum
antacids reduce the concentration of octreotide in the serum
antacids reduce the concentration of octreotide in the serum
antacids reduce the concentration of octreotide in the serum
antacids reduce the concentration of octreotide in the serum
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
octreotide: they may diminish the serum concentration of antacids
octreotide: they may diminish the serum concentration of antacids
octreotide: they may diminish the serum concentration of antacids
octreotide: they may diminish the serum concentration of antacids
octreotide: they may diminish the serum concentration of antacids
It may diminish the effects when combined with copper CU 64 dotatate by the receptor binding mechanism
octreotide exerts its influence on gallium ga 68 dotatate by engaging in receptor binding competition, thereby diminishing its effects
octreotide: they may diminish the serum concentration of antacids
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
It may enhance the QTc interval when combined with efavirenz
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may increase the QTc prolonging effect of QTc prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may increase the QTc-prolonging effect when combined
may increase the QTc-prolonging effect of each other when combined
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with dabrafenib
may have an increased QTc-prolonging effect when combined with fluorouracil products
may have an increased QTc-prolonging effect when combined with haloperidol
may have an increased QTc-prolonging effect when combined with ondansetron
may have an increased QTc-prolonging effect when combined with pentamidine
hydroxyzine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
pacritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
adverse effects or toxic effects of lacosamide are increased by antiarrhythmic agents when used in combination
amitriptyline: it may increase the risk or severity of QTc prolongation agents
benserazide: it may increase the risk or severity of QTc prolongation agents
it increases the toxicity of octreotide by affecting the QTc interval
it decreases the level of methadone by inhibiting gastrointestinal absorption
Octreotide is a synthetic analog of the naturally occurring hormone somatostatin. It acts on various receptors in the body and exerts multiple actions, making it a versatile medication used in different medical conditions. As a gastrointestinal agent, octreotide belongs to the antisecretory subclass of antidiarrheals, and it helps to treat diarrhea associated with certain pathophysiological conditions. Here are the primary actions and the spectrum of octreotide:
Actions of Octreotide:
Inhibition of Hormone Release: Octreotide acts as an inhibitor of hormone release, particularly certain gastrointestinal hormones, including gastrin, secretin, cholecystokinin (CCK), and vasoactive intestinal peptide (VIP). By inhibiting the secretion of these hormones, octreotide reduces excessive stimulation of the digestive system, which can help control diarrhea and reduce fluid and electrolyte loss.
Slowing of Gastrointestinal Motility: Octreotide can slow down the movement of the intestines, leading to increased transit time. This effect helps in reducing the frequency and urgency of bowel movements, providing relief from diarrhea.
Vasoconstriction: Octreotide has vasoconstrictive properties, meaning it can narrow blood vessels. This effect is useful in certain medical conditions where excessive blood flow needs to be reduced, such as in the treatment of acute bleeding from esophageal varices.
Inhibition of Growth Hormone: Octreotide can also suppress the release of growth hormone from the pituitary gland. It is used to manage medical conditions associated with excess growth hormone secretion, such as acromegaly and certain pituitary tumors.
Spectrum of Octreotide:
Diarrhea Associated with Neuroendocrine Tumors: Octreotide is commonly used to manage diarrhea and other symptoms associated with neuroendocrine tumors, including carcinoid tumors, gastrinomas, and vasoactive intestinal peptide-secreting tumors (VIPomas).
Postoperative Diarrhea: After certain gastrointestinal surgeries, some patients may experience diarrhea due to increased hormonal release or altered motility. Octreotide can be used to manage postoperative diarrhea in these cases.
Acute Bleeding from Esophageal Varices: Octreotide is used as an adjuvant treatment to reduce acute bleeding from esophageal varices, which are dilated veins in the esophagus that can rupture in patients with liver cirrhosis.
Acromegaly: In cases of acromegaly, a condition characterized by excess growth hormone secretion, octreotide can be used to control symptoms and reduce growth hormone levels.
Frequency defined
10 %Â
Nausea Â
Diarrhea Â
Hyperhidrosis Â
Headache Â
Arthralgia Â
Asthenia Â
Nausea Â
Peripheral swelling Â
Diarrhea Â
Increased blood glucose Â
Abdominal discomfort Â
Vomiting Â
Dyspepsia Â
Sinusitis Â
1-10%Â
Urinary tract infection
Pain  Â
Dyspepsia Â
Large intestine polyp Â
Cholelithiasis Â
Back pain Â
Dizziness Â
Abdominal painÂ
Fatigue Â
Hypertension Â
Upper respiratory tract infection Â
Cholelithiasis Â
Conduction abnormalitiesÂ
Sandostatin H4Â Â
Arrhythmias Â
Headache Â
Pain on injection Â
Goiter Â
Hypoglycemia Â
Dizziness Â
Frequency undefined
JaundiceÂ
HepatitisÂ
CellulitisÂ
NeuritisÂ
ArthritisÂ
Black Box Warning:
None
the drug is contraindicated in patients who are hypersensitive to octreotide or any other excipients of the formulation Â
Pregnancy consideration: Octreotide should be used in pregnancy only if the assumed benefits outweigh potential risksÂ
Breastfeeding warnings: No data available regarding the excretion of octreotide in human breast milkÂ
Pregnancy category:Â
Â
Administration:
Octreotide is a synthetic analogue of somatostatin, a hormone that inhibits the release of various hormones and other substances in the body. As you mentioned, octreotide is used to treat diarrhea associated with certain conditions, particularly those involving excessive hormone secretion. It is available in various formulations, including injectable forms and long-acting release preparations. Here’s how octreotide is commonly administered:
Subcutaneous Injection (Subcut): This is the most common route of administration for immediate-release octreotide. The drug is injected under the skin into the fatty tissue, usually in the upper arm, thigh, or abdomen. Subcutaneous injections are relatively easy to perform and can be done by the patient or a caregiver once proper training is provided.
Intramuscular Injection (IM): In some cases, immediate-release octreotide can be administered via the intramuscular route, where the drug is injected into a muscle. However, this route is less commonly used than the subcutaneous route.
Intravenous Infusion (IV): In certain situations, such as when rapid onset of action is needed, or in critically ill patients, octreotide can be given intravenously through a continuous infusion. This is typically performed in a hospital setting under close medical supervision.
Long-Acting Release (LAR) Injection: Long-acting octreotide formulations are available for conditions requiring prolonged suppression of hormone secretion. These are administered less frequently (e.g., once every 2-4 weeks) compared to immediate-release forms. Long-acting injections are typically given deep into the muscle (intramuscular) by a healthcare professional.
Patient information leafletÂ
Generic Name: OctreotideÂ
Pronounced: Ok-Tree-oh-tideÂ
Why do we use Octreotide?Â
Octreotide is a synthetic analog of the hormone somatostatin, and it is used for various medical conditions due to its ability to inhibit the release of several hormones and neurotransmitters. Here are some of the main uses of octreotide:
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
